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ABSTRACT: The main objective of this study was to determine
whether (E)-3-furan-2-yl-N-p-tolyl-acrylamide (PAM-2) and its
structural derivative DM489 produce anti-neuropathic pain activity
using the streptozotocin (STZ)- and oxaliplatin-induced neuro-
pathic pain animal models. To assess possible mechanisms of
action, the pharmacological activity of these compounds was
determined at α7 and α9α10 nicotinic acetylcholine receptors
(nAChRs) and CaV2.2 channels expressed alone or coexpressed
with G protein-coupled GABAB receptors. The animal results
indicated that a single dose of 3 mg/kg PAM-2 or DM489
decreases STZ-induced neuropathic pain in mice, and chemo-
therapy-induced neuropathic pain is decreased by PAM-2 (3 mg/
kg) and DM489 (10 mg/kg). The observed anti-neuropathic pain
activity was inhibited by the α7-selective antagonist methyllycaco-
nitine. The coadministration of oxaliplatin with an inactive dose (1 mg/kg) of PAM-2 decreased the development of neuropathic
pain after 14, but not 7, days of cotreatment. The electrophysiological results indicated that PAM-2 potentiates human (h) and rat
(r) α7 nAChRs with 2−7 times higher potency than that for hCaV2.2 channel inhibition and an even greater difference compared to
that for rα9α10 nAChR inhibition. These results support the notion that α7 nAChR potentiation is likely the predominant molecular
mechanism underlying the observed anti-nociceptive pain activity of these compounds.
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■ INTRODUCTION
Nicotinic acetylcholine receptors (nAChRs) such as the α7
and α9α10 subtypes are members of the Cys-loop ligand-gated
ion channel superfamily, which also comprises the γ-amino-
butyric acid type A (GABAA), glycine, and serotonin type 3 (5-
HT3) receptors.
1 Both α7 and α9α10 subtypes have been
reported to be involved in pain-related processes, including
neuropathic pain and chronic inflammation. α9α10 nAChRs
are expressed mainly in outer hair cells of the cochlea,2
endocrine cells,3 and various immune cells,4 and its inhibition
decreases neuropathic pain in animal models.5,6 On the
contrary, α7 nAChRs are abundantly expressed in the brain
and peripheral tissues, including immunocompetent cells and
nociceptive dorsal root ganglion (DRG) neurons, and different
studies confirmed the role of this receptor subtype in
inflammatory and neuropathic pain.6−9 Although the use of
α7 knockout (KO) mice in principle supported the role of α7
nAChRs in pain processes, they are somehow controversial.
For instance, intraplantar injections of Complete Freund’s
Adjuvant, but not chronic constriction nerve injury, increased
hyperalgesia and allodynia in α7 KO mice compared to wild-
type mice, and the anti-nociceptive effects of systemic nicotine
were observed only in wild-type animals.10 Although α7 KO
mice did not show differences in thermal and mechanical
hypersensitivity, they were less susceptible to the anti-
nociceptive activity of choline (an agonist with relatively
higher selectivity for α7 nAChRs) infusions compared to wild-
type mice.11
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Previous attempts to alleviate pathological conditions
involving chronic pain were focused on selective α7 nAChR
agonists.8,12 However, their therapeutic efficacies have been
limited due to potential side effects and increased receptor
desensitization. Several laboratories have focused on the use of
positive allosteric modulators (PAMs) with high selectivity for
α7 nAChRs (e.g., PNU-120596 and PAM-2), which induce
anti-nociceptive and anti-inflammatory effects in various
animal models.6,13,14 In this regard, we compared the anti-
neuropathic pain activity of PAM-2 [(E)-3-furan-2-yl-N-p-
tolyl-acrylamide]15 with that of a novel structural derivative
with relatively higher brain penetration, DM489 [(E)-3-(furan-
2-yl)-1-(indolin-1-yl)prop-2-en-1-one)] (see 3D structures in
Figure 1), by using the oxaliplatin- and streptozotocin (STZ)-
induced neuropathic pain models.5,16−18
To assess the molecular mechanisms underlying the
observed anti-neuropathic pain activity of PAM-2 and
DM489, their pharmacological activities were determined at
α7 and α9α10 nAChRs heterologously expressed in Xenopus
laevis oocytes using the two-electrode voltage clamp recording
technique. Given that voltage-gated N-type calcium (CaV2.2)
channels modulated by G protein-coupled GABA type B
receptors (GABABRs) have been implicated in pain-related
processes,5,19,20 the activity of PAM-2 and DM489 was also
investigated on CaV2.2 channels expressed alone or coex-
pressed with GABABRs using the whole-cell patch clamp
recording technique.
This study clearly demonstrated that both PAM-2 and
DM489 induce anti-neuropathic pain activity in mice and that
α7 nAChR potentiation, rather than α9α10 nAChR and/or
CaV2.2 channel inhibition, is likely the predominant molecular
mechanism underlying this activity. The results also suggested
that PAM-2 and DM489 might be used for the prevention and
treatment of (chronic) neuropathic pain, especially in
chemotherapy and diabetes conditions.
■ RESULTS AND DISCUSSION
Chemical Synthesis. DM489 was synthesized by reacting
(E)-3-(furan-2-yl)acrylic acid with indoline, using N-(3-
dimethylaminopropyl)-N′-ethylcarbodiimide (EDC) and 1-
hydroxybenzotriazole hydrate (HOBt) as coupling reagents
(Scheme 1). For convenience, the same method was also
applied to the preparation of PAM-2, using p-toluidine as a
reactant. This procedure gave high yields for both compounds
and better purity (>99.5% for PAM-2 and >95% for DM489)
than those obtained by previous methods.15
Brain Permeability Prediction for PAM-2 and DM489.
To predict whether PAM-2 and DM489 can penetrate the
brain, their lipophilicity (LogP) and blood−brain barrier
penetration (LogBB) values were calculated (Table 1). The
results indicated that, although both compounds have similar
lipophilicity (LogP > 2), DM489 has a relatively higher brain
permeability (0.17) than that of PAM-2 (0.09). This is a
consequence of the higher polarity of the secondary amine of
PAM-2, which has a H-bond donor, whereas DM489 is a
tertiary amine with no H-bond donor (see Figure 1). Previous
in vivo animal studies showed that intraperitoneal (ip)
injections of PAM-2 induced several behavioral effects in
mice,21−23 thus suggesting an active brain permeability of
PAM-2.
PAM-2 or DM489 Decreased Drug-Induced Neuro-
pathic Pain in Mice. The pain-relieving properties of PAM-2
and DM489 were evaluated using different animal models of
neuropathic pain. In Figure 2, the effects of these PAMs against
streptozotocin (STZ)-induced diabetic neuropathic pain are
shown. STZ-induced hypersensitivity to cold noxious stimuli
(i.e., allodynia-like measurements using the cold plate test) was
developed, where STZ decreased the pain threshold (i.e.,
increased pain sensitivity) to 9.8 ± 0.4 s in comparison to
those of vehicle-treated animals (18.5 ± 0.2 s, n = 10) (one-
way ANOVA; P < 0.01). Interestingly, the treatment with 3
mg/kg, but not 1 mg/kg PAM-2, was able to significantly (P <
0.05) decrease neuropathic pain between 15 and 45 min, with
complete reversal at 30 min. On the contrary, DM489 was
active at 3 (P < 0.05) and 10 (P < 0.01) mg/kg compared to
vehicle-treated animals. No statistical differences were
observed between 3 mg/kg PAM-2 and DM489 (P > 0.05).
To study the drug’s profile against a different model of
chronic pain, neuropathic conditions were evoked using the
neurotoxic anti-cancer agent oxaliplatin.5,16 Treatment (ip)
with 2.4 mg/kg oxaliplatin progressively developed neuro-
pathic pain in mice as evaluated by the cold plate test. The
licking latency decreased to 9.5 ± 0.2 s in comparison to in
vehicle-treated animals (18.7 ± 0.2 s, n = 10) (P < 0.01)
Figure 1. 3D molecular structure of PAM-2 [(E)-3-furan-2-yl-N-p-
tolyl-acrylamide] and DM489 [(E)-3-(furan-2-yl)-1-(indolin-1-yl)-
prop-2-en-1-one] with the van der Waals surface surrounding the
molecule (stick model) and colored according to atom type: O (red),
N (blue), H (white), and C (gray). Representations were generated
using DSViewer Pro 6.0 (Accelrys, San Diego, CA).
Scheme 1. Chemical Synthesis of PAM-2 [(E)-3-Furan-2-yl-
N-p-tolyl-acrylamide] and DM489 [(E)-3-(Furan-2-yl)-1-
(indolin-1-yl)prop-2-en-1-one]a
aEt3N, triethylamine; EDC, N-(3-dimethylaminopropyl)-N′-ethyl-
carbodiimide; HOBt, 1-hydroxybenzotriazole hydrate.
Table 1. Lipophilicity (LogP) and Blood−Brain Barrier
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(Figure 3). The effect elicited by a single p.o. administration of
PAM-2 (Figure 3A) or DM489 (Figure 3B) was subsequently
evaluated on day 15. Bonferroni post hoc analyses indicated
that a dose of 3 mg/kg (P < 0.01), but not 1 mg/kg, PAM-2
induced pain relief, starting 15 min after treatment and lasting
for 45 min. In addition, DM489 produced pain relief at doses
of 10 and 30 mg/kg (P < 0.01), and the effect was quicker
(peak at 15 min) than that for PAM-2 (peak at 30 min). These
results indicated that both compounds at different doses are
capable of inducing anti-nociceptive effects but that the onset
of PAM-2’s action is double that of DM489.
Anti-Neuropathic Pain Activity of PAM-2 and DM489
is Mediated by α7-Containing nAChRs. To determine
whether the anti-neuropathic pain activity of PAM-2 and
DM489 was mediated by α7-containing nAChRs, the effect of
6 mg/kg methyllycaconitine citrate (MLA), an α7-selective
antagonist,24 was determined on mice treated with an active
dose of PAM-2 (3 mg/kg) (Figure 4A) or DM489 (30 mg/kg)
(Figure 4B). Statistical analyses of the results indicated that the
anti-neuropathic pain effect elicited by PAM-2 and DM489
was completely blocked by MLA (P < 0.01), whereas MLA did
not change per se the neuropathic pain effect elicited by
oxaliplatin.
PAM-2 Decreased the Development of Oxaliplatin-
Induced Neuropathic Pain. To determine whether PAM-2
decreases the development of oxaliplatin-induced neuropathic
pain, an inactive dose of PAM-2 (1 mg/kg) was coadminis-
tered with 2.4 mg/kg oxaliplatin using the same protocol as for
oxaliplatin alone, and cold plate tests were performed on day
15. Bonferroni post hoc analyses indicated that PAM-2 +
oxaliplatin-treated animals have a significantly higher pain
threshold compared to oxaliplatin-treated animals after 14, but
not 7, days of treatment (P < 0.01) (Figure 5A). Interestingly,
an additional administration of PAM-2 30 min after the
described cotreatment, produced a higher pain reversion in the
0−30 min time regime compared to the same period in the
previous cotreatment (P < 0.01; Figure 5B).
The animal results indicated that that a single dose of either
3 mg/kg PAM-2 or DM489 was able to decrease STZ-induced
diabetic neuropathic pain. In addition, PAM-2 decreased
oxaliplatin-induced neuropathic pain at a lower dose (3 mg/
kg) than that used with DM489 (10 mg/kg); however, the
latter produced a faster onset of action than that for PAM-2.
Since electrophysiology results showed that DM489 and PAM-
2 enhance ACh-evoked rα7 activity with similar potency and
efficacy, a possible explanation for the anti-nociceptive
differences observed between these compounds might be
based on the inhibitory component observed for DM489, but
not for PAM-2, and/or distinct outcomes between drug-
induced neuropathic models (i.e., chemotherapy-induced
neuropathy is in general more painful than that elicited by
diabetic drugs). In addition, the faster onset observed for
DM489 compared to PAM-2 could be due to the relatively
greater ability of the former drug to cross the blood−brain
barrier.
Additional animal experiments also showed that PAM-2 can
decrease the development of oxaliplatin-induced neuropathic
pain in mice, which could be of clinical relevance in the
prevention of chemotherapy-induced chronic pain in cancer
Figure 2. Effect of (A) PAM-2 and (B) DM489 on streptozotocin
(STZ)-induced neuropathic pain in mice. Mice (n = 10/condition)
were treated with a single injection (ip) of 100 mg/kgSTZ (□) to
develop neuropathic pain. On day 15, (A) PAM-2 [1 (◊) and 3 mg/
kg (Δ)] or (B) DM489 [3 (Δ) and 10 (○) mg/kg] was administered
per os (p.o.), and the response to a thermal stimulus was subsequently
evaluated by the cold plate test. The licking latency (mean ± SEM in
seconds) for the first signs of pain-related behavior was recorded
before and 15, 30, 45, and 60 min after treatment. Bonferroni post hoc
analyses indicated that STZ + vehicle (□) induced neuropathic pain
during the whole testing time (i.e., 0−60 min) [P < 0.01 vs vehicle +
vehicle-treated mice (●)] and that 3 mg/kg PAM-2 (Δ) decreased
drug-induced neuropathic pain at 15 (P < 0.05) and 30 (P < 0.01)
min period (A), whereas 3 (Δ) and 10 (○) mg/kg DM489 decreased
neuropathic pain during the 15−30 and 15−45 min periods (P <
0.01), respectively, compared to that for STZ + vehicle (□).
Figure 3. Effect of (A) PAM-2 and (B) DM489 on oxaliplatin-
induced neuropathic pain in mice. Mice (n = 10/condition) were
treated (ip) with 2.4 mg/kg oxaliplatin to induce neuropathic pain.
On day 15, (A) PAM-2 [1 (Δ) and 3 mg/kg (○)] or (B) DM489 [10
(Δ) and 30 (○) mg/kg] was administered (p.o.), and the response to
a thermal stimulus was subsequently evaluated by the cold plate test.
The licking latency (mean ± SEM) for the first signs of pain-related
behavior was recorded before and 15, 30, 45, and 60 min after
treatment. Bonferroni post hoc analyses indicated that oxaliplatin +
vehicle induced neuropathic pain (□) during the whole testing time
[P < 0.01 vs vehicle + vehicle-treated mice (●)] and that 3 (○) (P <
0.01), but not 1 mg/kg (Δ) (P > 0.05), PAM-2 decreased drug-
induced neuropathic pain during the 15−45 min period (A), whereas
10 mg/kg DM489 decreased neuropathic pain during the 15−30 min
period (Δ) and 30 mg/kg DM489 decreased neuropathic pain during
the 15−45 min period (○) (P < 0.01 for both) (B), compared to
oxaliplatin + vehicle-treated mice (□).
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patients, especially considering that PAM-2 has a higher
efficacy than that of DM489. Our study based on drug-induced
neuropathic pain models and especially the chemotherapy-
based model, which mainly induces neuropathy toxicity
without an inflammatory component, expanded previous
results showing that PAM-2 reduces neuropathic pain induced
by sciatic nerve ligation,25 which has a strong inflammatory
component.16
PAM-2 and DM489 Potentiated ACh-Activated α7
nAChRs in a Concentration-Dependent Manner. The
activity of PAM-2 and DM489 was determined at human and
rat α7 nAChRs (>90% amino acid sequence homology)
heterologously expressed in X. laevis oocytes using the two-
electrode voltage clamp recording technique. At 10 μM, PAM-
2 and DM489 potentiated ACh-evoked hα7 currents by 30 ±
4% and 27 ± 6% (n = 5−6), respectively, in a reversible
manner, indicating that receptors are not continuously
stimulated upon washout (Figure 6A). Similarly, 10 μM
PAM-2 and DM489 potentiated rα7 nAChR-mediated
currents by 15 ± 4% and 30 ± 8% (n = 5−8), respectively
(Figure 7A).
The concentration−response relationships for PAM-2 and
DM489, relative to that induced by ACh at 20% maximal
effective concentrations (EC20) [i.e., 30 μM for hα7, and 160
μM for rα7 (see Figure 7B)], indicated that both compounds
enhanced ACh-evoked currents at hα7 (Figure 6B) and rα7
(Figure 7C) nAChRs with comparable potencies (Table 2).
Although both PAM-2 and DM489 enhanced rα7 nAChRs
with 3- to 4-fold higher potency than that at hα7 nAChRs,
their efficacies (i.e., ΔEmax) were higher at hα7 nAChRs
(120%−150%) compared to that at rα7 nAChRs (∼30%)
(Table 2). The calculated nH values (i.e., nH > 1.5) (Table 2)
support a cooperative mechanism at both hα7 and rα7
nAChRs.
By using the two-component Hill equation [see eq.] 1], we
were able to discriminate the potentiating and inhibitory
effects of both PAM-2 and DM489 at α7 nAChRs. The results
indicated that concentrations above 100 μM PAM-2 and 30
μM DM489 started to inhibit, probably by a negative allosteric
modulatory mechanism at rα7 (Figure 7C), but not hα7
(Figure 6B), nAChRs. Comparison of the half-maximal
effective and inhibitory concentrations (EC50 and IC50,
respectively) (Table 2) showed that PAM-2 potentiated rα7
nAChRs with >8-fold higher potency than that elicited by
inhibition (12 vs >100 μM), whereas DM489 potentiated the
rα7 nAChR with ∼6-fold higher potency than that elicited by
inhibition (9 vs 56 μM).
PAM-2 and DM489 Inhibited rα9α10 nAChRs with
Different Potencies and in a Voltage-Independent
Manner. To determine the inhibitory activity of PAM-2 and
DM489 at rα9α10 nAChRs, two-electrode voltage clamp
experiments were performed on nAChRs expressed in Xenopus
oocytes. Both compounds inhibit ACh (10 μM)-evoked
currents in a concentration-dependent manner (Figure 8A),
and the concentration−response analyses (Figure 8B) showed
that the inhibitory potency for DM489 was 4-fold higher than
Figure 4. Effect of methyllycaconitine (MLA) on the anti-neuropathic
pain activity elicited by (A) PAM-2 and (B) DM489. Mice (n = 10/
condition) were treated (ip) with 2.4 mg/kg oxaliplatin to develop
neuropathic pain. On day 15, 6 mg/kg MLA was administered (ip) 15
min before (A) 3 mg/kg PAM-2 (p.o.) (□) or (B) 30 mg/kg DM489
(□). The response of MLA to the respective effect elicited by (A)
PAM-2 (□)and (B) DM489 (□) was subsequently compared to that
for PAM-2 (◊) and DM489 (◊) by the cold plate test. The licking
latency (mean ± SEM) for the first signs of pain-related behavior was
recorded before and 15, 30, 45, and 60 min after treatment.
Bonferroni post hoc analysis indicated that MLA inhibited the anti-
neuropathic pain effect elicited by PAM-2 during the 15−45 min
period (□) and by DM489 during the 15−30 min period (□) (P <
0.01 for both), compared to the respective drug + vehicle-treated
animals (◊), whereas MLA + oxaliplatin-treated animals (Δ) were not
different from oxaliplatin + vehicle treated animals (P > 0.05) (○).
Figure 5. PAM-2 decreased the development of oxaliplatin-induced
neuropathic pain. Mice (n = 10/condition) were treated (ip) with 2.4
mg/kgoxaliplatin alone (gray) or coadministered with an inactive
dose (1 mg/kg; p.o.) of PAM-2 (black). (A) Effect of PAM-2 after 7
and 14 days of cotreatment with oxaliplatin. Cold plate tests were
determined 24 h after the last administration and the pain threshold
values (mean ± SEM) compared between drug- and vehicle-treated
animals (white). Bonferroni post hoc analyses indicated that oxaliplatin
+ vehicle induced neuropathic pain after 7 and 14 days of treatment
[**P < 0.01 vs vehicle + vehicle-treated mice (white)], and that PAM-
2 + oxaliplatin decreased neuropathic pain after 14, but not 7, days of
treatment [ ̂P̂ < 0.01 vs oxaliplatin + vehicle-treated mice (gray)]. (B)
Thirty minutes after an additional administration of 1 mg/kg PAM-2,
the pain threshold (mean ± SEM) was recorded at 0, 15, 30, 45, and
60 min. Bonferroni post hoc analyses indicated that oxaliplatin +
vehicle-treated mice developed neuropathic pain during the whole
testing time (□) [P < 0.01 vs vehicle + vehicle-treated mice (○)], and
that PAM-2 decreased neuropathic pain (●) during the 0−30 min
period (P < 0.01 vs oxaliplatin + vehicle-treated mice).
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that for PAM-2 (Table 2). Given that the observed nH values
were close to 2 (Table 2) indicated that the inhibitory process
is mediated by a cooperative mechanism.
Moreover, the voltage-dependence of rα9α10 inhibition, as
shown in the representative current−voltage (I−V) curves
(Figure 8C), indicated that DM489 inhibition was voltage-
independent. Specifically, responses were equally inhibited
(Paired Student’s t test; P = 0.38) by both negative (−90 mV)
hyperpolarized potentials (% I/Imax = 63 ± 8%, n = 6) and
positive (+40 mV) depolarized potentials (57 ± 6%, n = 6)
(Figure 8C), suggesting that the inhibition is voltage-
independent. Although this result supports a competitive
inhibitory mechanism, we cannot rule out the possibility of
channel pore blockade at higher concentrations. Since PAM-2
was >7-fold more potent enhancing rα7 than inhibiting rα9α10
nAChRs, it is unlikely that the latter subtype is involved in the
anti-neuropathic pain activity elicited by these compounds.
PAM-2 and DM489 Inhibited CaV2.2 Channels Alone
but Not Those Coupled to GABABRs. A class of α-
conotoxins that exhibit potent anti-nociceptive activity have
been shown to not only inhibit α9α10 nAChRs but also
CaV2.2 channels via G protein-coupled GABAB receptor
activation.19,26 Given that neither PAM-2 nor DM489 have
been tested on either GABABRs or CaV2.2 channels, we
investigated the activity of these compounds on HEK293T
cells expressing hCaV2.2 channels alone or coexpressing
GABABRs and CaV2.2, respectively.
Depolarization-activated Ba2+ currents (IBa) recorded from
HEK293T cells transiently cotransfected with GABABR and
hCaV2.2 channels were reversibly inhibited by PAM-2 and
DM489 but were not antagonized by 1 μM CGP55845, a
selective GABABR antagonist. In contrast, the inhibition of IBa
by 50 μM baclofen, a GABABR agonist, was antagonized by
CGP55845 (Figure 9A). However, in HEK293T cells
expressing hCaV2.2 alone, both PAM-2 (Figure 9B) and
DM489 (Figure 9C) inhibited whole-cell IBa values in a
concentration-dependent manner, and the calculated IC50
values were 89 ± 15 and 122 ± 25 μM (n = 4), respectively
(Table 2). These results demonstrated that both PAM-2 and
DM489 inhibit hCaV2.2 channels directly without involving
the G protein-coupled GABABR. Thus, these compounds must
have a mechanism distinct to that of analgesic α-conotoxins
(e.g., Vc1.1 and Rg1A), which inhibit GABABR coupled
CaV2.2 channels.
19 PAM-2 and DM489 appear to act similar to
coronaridine congeners, which also exhibit anti-neuropathic
pain activity and inhibit CaV2.2 channels directly.
5
Previous studies clearly identified CaV2.2 channels in pain-
related mechanisms and as targets for the anti-nociceptive
activity of a variety of selective inhibitors.5,19,20,27 Moreover,
both CaV2.2 channels and α7 nAChRs are expressed in DRG
neurons, where they modulate the release of glutamate onto
dorsal horn neurons, enhancing excitatory signaling in these
neurons.6,9 Although this overlapping expression opens the
possibility for complementary mechanisms, our study demon-
strated that PAM-2 and DM489 inhibit CaV2.2 channels with
Figure 6. Effect of PAM-2 and DM489 at ACh-activated hα7 nAChRs expressed in Xenopus oocytes. (A) Representative ACh (30 μM)-evoked hα7
currents obtained at −80 mV in the absence and presence of 10 μM PAM-2 or DM489 and after washout. ▽, ACh alone; ▼, coapplication of ACh
+ compound after 5 min incubation () with compound alone; ▽, ACh alone after washout. (B) Concentration−response relationships obtained
for PAM-2 (○) and DM489 (▲)-induced potentiation of ACh-evoked current amplitude at hα7 nAChRs. Current amplitudes (mean ± SEM; n =
5−6) were normalized to the response elicited by 30 μM ACh alone (corresponding to its EC20 at hα7 nAChRs). The calculated potentiating EC50,
ΔEmax, and nH values are summarized in Table 2.
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potencies relatively lower than that determined for α7 nAChR
potentiation (see Table 2), suggesting that the latter is the
predominant mechanism underlying the observed anti-neuro-
pathic activity in mice.
The widespread expression of α7 nAChRs in neurons,
microglia, astrocytes, and lymphocytes suggests their pre-
eminent role in neuro-immune crosstalk.7 Accordingly, a
protective α7-mediated microglial function has been detected
in hippocampal cultures under brain ischemic conditions.28
Studies showing that nAChR ligands lose anti-nociceptive
activity when α7 KO mice are used10,11 support the concept
that alterations in peripheral and central mechanisms involving
α7 nAChRs could be also involved in neuropathic pain. In
particular, α7-selective agonists produced neuroprotective
effects by preventing oxaliplatin-induced damages in peripheral
nerves and DRG neurons,8,12 suggesting that α7 nAChRs
expressed in DRG neurons are involved in nociception
mechanisms.9 Moreover, oxaliplatin treatment induced α7
nAChR downregulation in the peripheral and central nervous
systems, whereas the repeated treatment with selective agonists
Figure 7. Effect of PAM-2 and DM489 on ACh-activated rα7 nAChRs expressed in Xenopus oocytes. (A) Representative ACh (160 μM)-evoked
rα7 currents obtained at −80 mV in the absence and presence of 10 μM PAM-2 or DM489 and after compound washout. ▽, ACh alone; ▼,
coapplication of ACh + compound after 5 min incubation () with compound alone; ▽, ACh alone after washout. (B) Concentration−response
relationships for ACh-evoked current amplitudes at rα7 nAChRs. Current amplitudes (mean ± SEM; n = 5) were normalized to the response
elicited by 30 mM ACh, and an ACh EC50 value of 575 ± 32 μM was calculated. (C) Concentration−response relationships obtained for PAM-2
(○) and DM489 (▲)-induced potentiation of ACh-evoked current amplitude at rα7 nAChRs. Current amplitudes (mean ± SEM; n = 5−8) were
normalized to the response elicited by 160 μM ACh alone [corresponding to its EC20 at rα7 nAChRs; see (B)]. The calculated EC50, ΔEmax, IC50,
and nH values are summarized in Table 2.
Table 2. Pharmacological Activity of PAM-2 and DM489 at α7 and α9α10 nAChR Subtypes and CaV2.2 Channels
potentiation inhibition
molecular target compound EC50 (μM) nH ΔEmax (% control) IC50 (μM) nH
hα7a PAM-2 39 ± 6 1.50 ± 0.26 155 ± 9 no activity
DM489 34 ± 7 1.62 ± 0.45 126 ± 14 no activity
rα7b PAM-2 12 ± 3 2.28 ± 1.41 35 ± 4 >100e
DM489 9 ± 3 2.81 ± 3.47 32 ± 6 56 ± 14e 2.25 ± 0.60e
rα9α10c PAM-2 no activity 174 ± 18 2.17 ± 0.30
DM489 no activity 39 ± 2 2.41 ± 0.27
hCaV2.2
d PAM-2 no activity 89 ± 15 1.2 ± 0.2
DM489 no activity 122 ± 25 1.0 ± 0.1
aValues were calculated from Figure 6B. bValues were calculated from Figure 7C. cValues were obtained from Figure 8B. dValues were obtained
from Figure 9C. eValues obtained by using two-component Hill eq 1.
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Figure 8. Effect of DM489 and PAM-2 on ACh-activated rα9α10 nAChRs expressed in Xenopus oocytes. (A) Peak current amplitude of α9α10
nAChRs elicited by 10 μM ACh is diminished by either DM489 or PAM-2 in a concentration-dependent manner. (B) Concentration−response
curves (mean ± SEM; n = 3−6) for the inhibitory activity of DM489 (□) and PAM-2 (■). Response was normalized to that elicited by 10 μM
ACh (control set as 100%). The IC50 and nH values were obtained by nonlinear least-squares fit and summarized in Table 2. (C) Current−voltage
relationship for DM489 was obtained by applying 2 s voltage ramps from −120 to +50 mV, 10 s after the peak response to 10 μM ACh from a
holding potential (Vhold) of −70 mV, in the absence (black line) and presence (gray line) of 30 μM DM489. Paired Student’s t test analysis showed
that DM489’s inhibition is not significantly different (P = 0.38) between −90 mV (63 ± 8%, n = 6) and +40 mV (57 ± 6%, n = 6).
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prevented receptor dysregulation and upregulated α7 nAChRs
in peripheral nerves and spinal cord as well as increased the
density of glial cells in spinal cord and brain areas of naiv̈e
rats.8 In conclusion, the PAM-induced α7 nAChR potentiation
observed in our experiments could beneficially affect glial
signaling, leading to pain control along with a significant
neuroprotective effect. Since the repeated administration of
α7-PAMs does not change the levels of α7 nAChRs in the
brain,29 a mechanism involving PAM-induced up-regulation as
part of the anti-neuropathic pain effects elicited by PAM-2 and
DM489 can be ruled out. Considering that PAM-2 delays
receptor desensitization,30 corresponding to the definition of
type II PAMs, the possibility that α7 nAChR desensitization
accounts for the anti-neuropathic pain effect of PAM-2 can also
be dismissed.
■ CONCLUSIONS
The main objective of this study was to determine whether
PAM-2 and its structural derivative DM489 have anti-
neuropathic pain activity in mice by using the STZ- and
oxaliplatin-induced neuropathic pain models. To define the
mechanisms of action of these compounds, their pharmaco-
logical activities were determined at α7 and α9α10 nAChRs, as
well as CaV2.2 channels alone or coupled with GABABRs by
electrophysiological recordings. This study clearly demon-
strates that PAM-2 and DM489 reduce drug-induced neuro-
pathic pain in mice and that α7 nAChR potentiation is likely
the predominant molecular mechanism underlying this activity.
Our results also suggest that PAM-2 and DM489 might be
used for the prevention and treatment of chronic neuropathic
pain, especially in chemotherapy and diabetes conditions.
Figure 9. Inhibitory activity of PAM-2 and DM489 at hCaV2.2 channels and GABABRs heterologously expressed in HEK293T cells. (A) Time-
dependent plot of peak Ba2+ current (IBa) amplitudes before, during, and upon washout of 50 μM (±)-baclofen (Bac), 100 μM PAM-2, and 100
μM DM489, in the continuous presence of the selective GABABR antagonist, CGP55845 (1 μM). (B) Representative depolarization-activated IBa
elicited from a holding potential of −80 mV to a test potential of −10 mV (50 ms duration; 0.1 Hz) from HEK293T cells expressing CaV2.2
channels in the (a) absence and presence of (b) 30 and (c) 300 μM PAM-2 or DM489. (C) Concentration−response relationship for PAM-2 (○)
and DM489 (Δ) inhibition of hCaV2.2 channels expressed alone in HEK293T cells (mean ± SEM; n = 4). The calculated IC50 and nH values are
summarized in Table 2.
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■ METHODS
Chemicals. Acetylcholine chloride (ACh), (±)-baclofen, ethyl 3-
aminobenzoate methanesulfonate and BAPTA-AM were obtained
from Sigma-Aldrich (St. Louis, MO), Streptozotocin (STZ), glucose,
carboxymethyl cellulose, (E)-3-(furan-2-yl)acrylic acid, 1-hydroxy-
benzotriazole hydrate (HOBT), p-toluidine, indoline, and methyl-
lycaconitine citrate (MLA) were obtained from Sigma-Aldrich SRL
(Milan, Italy). Oxaliplatin was obtained from Carbosynth (Berkshire,
UK). CGP55845 hydrochloride was purchased from Tocris
Bioscience (Bristol, UK). HAM’s F10 medium, horse serum, and
hygromycin B were purchased from Thermo Fisher Scientific
(Waltham, MA). Fetal bovine serum (FBS) was obtained from
Bovogen (East Keilor, VIC, Australia) and Thermo Fisher Scientific.
DMEM, GlutaMAX, penicillin, and streptomycin were purchased
from Invitrogen Life Technologies (Carlsbad, CA). N-(3-Dimethyla-
minopropyl)-N′-ethylcarbodiimide hydrochloride was obtained from
Fluorochem (Glossop, UK). Salts and other compounds were of
analytical grade.
Synthesis of PAM-2 and Its Novel Derivative DM489. For the
synthesis of PAM-2 and DM489, a modification of the method
described previously was used.15 (E)-3-(Furan-2-yl)acrylic acid (1.0
mmol) was dissolved in anhydrous dichloromethane (5 mL), and the
solution was cooled to 0 °C. Then, triethylamine (2.0 mmol) and the
proper amine (p-toluidine for PAM-2 or indoline for DM489, 1.0
mmol) was added (see Scheme 1). The mixture was maintained at 0
°C and stirred for 1 h. Then, 1-hydroxybenzotriazole hydrate (HOBt)
(2.0 mmol) and N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide
hydrochloride (EDC HCl) (2.0 mmol) were sequentially added, and
the mixture was warmed to room temperature (RT) and stirred for 18
h. The mixture was next treated with dichloromethane (15 mL), and
the organic layer was washed twice with 6 N HCl (5 mL). After
drying with sodium sulfate, the solvent was removed under reduced
pressure, and the residue was purified by flash silica gel
chromatography [dichloromethane (99.9)/methanol (0.1), v:v],
giving each purified compound.
Chemical Characterization. The uncorrected melting point of
each compound was measured using a SMP3 apparatus (Stuart-
BioCote, Staffordshire, UK). 1H NMR and 13C NMR spectra were
recorded using a Bruker NMR 400 AVANCE spectrophotometer
(Faellanden, Switzerland). Samples were dissolved in CDCl3 and
placed in 5 mm NMR tubes. Measurements were taken using a CDCl3
lock and tetramethylsilane as the internal reference. ESI-MS spectra
were obtained using a Varian 1200L triple quadrupole system (Palo
Alto, CA), equipped with an electrospray ionization source (ESI).
Chromatographic separations were performed on a silica gel column
(40, 0.040−0.063 mm; Merck, Darmstadt, Germany) by flash
chromatography. Compounds were named following IUPAC rules
as applied by ChemBioDraw (version 14.0.0.117) software by
PerkinElmer (Waltham, MA).
PAM-2 [(E)-3-(Furan-2-yl)-N-(p-tolyl)acrylamide] (Figure 1). 1H
NMR (CDCl3, 400 MHz): δ 2.30 (s, 3H, CH3), 6.43 (dd, J = 3.3, 1.8
Hz, 1H), 6.50 (d, J = 19.1 Hz, 1H), 6.51 (s, 1H), 7.10 (d, J = 8.2 Hz,
2H), 7.40 (d, J = 1.3 Hz, 1H), 7.47−7.51 (m, 3H), 7.73 (bs, 1H, NH)
ppm. 13C NMR (CDCl3, 400 MHz): δ 20.9, 112.2, 114.2, 118.7,
120.0, 128.7, 129.5, 144.2, 151.3, 164.0 ppm. ESI-LC/MS
(C14H13NO2): m/z 228.0 [M + H]
+; mp 161−162 °C; yield 76.6%.
DM489 [(E)-3-(Furan-2-yl)-1-(indolin-1-yl)prop-2-en-1-one] (Fig-
ure 1). 1H NMR (CDCl3, 400 MHz): δ 3.15−3.21 (m, 2H), 4.21 (t, J
= 8.3 Hz, 2H), 6.46 (dd, J = 3.3, 1.8 Hz, 1H), 6.58 (d, J = 3.3 Hz,
1H), 6.71−6.77 (m, 1H), 7.00 (t, J = 7.4 Hz, 1H), 7.16−7.25 (m,
2H), 7.46 (d, J = 1.0 Hz, 1H), 7.56 (d, J = 15.1 Hz, 1H), 8.32 (bs,
1H) ppm. 13C NMR (CDCl3, 400 MHz): δ 27.9, 48.1, 112.3, 114.5,
116.6, 117.4, 123.8, 124.5, 127.5, 129.6, 144.2, 151.6, 164.1 ppm. ESI-
LC/MS (C15H13NO2): m/z 240.1 [M + H]
+; mp 113−114 °C; yield
87.3%.
Lipophilicity and Brain Permeability Properties of PAM-2
and DM489. To predict whether PAM-2 and DM489 cross the
blood−brain barrier, the lipophilicity (i.e., LogP) and brain
permeability (LogBB = Log[brain]/[plasma]) parameters were
calculated using Biovia Discovery Studio software (Dassault System̀es
Co., Waltham, MA). The scale for LogBB ranges from values ≥0.7
(very high brain penetration), 0.0−0.7 (high penetration), and < 0.0
to −0.52 (medium penetration) to ≤ −0.52 (low penetration). The
use of this software to estimate drug LogBB values has been validated
by the observed correlation between calculated and experimental
values.31
Animals. Male CD-1 albino mice (Envigo, Varese, Italy), 2−3
months old (22−25 g), were used. Animals were housed in CeSAL
(Centro Stabulazione Animali da Laboratorio, University of Florence)
and used at least 1 week after their arrival. Ten mice were housed per
cage (size 26 × 41 cm2); animals were fed a standard laboratory diet
and tap water ad libitum and kept at 23 ± 1 °C with a 12 h light/dark
cycle, with light at 7 am. All animal manipulations were carried out
according to the Directive 2010/63/EU of the European parliament
and of the European Union council (September 22, 2010) on the
protection of animals used for scientific purposes. Formal approval to
conduct animal experiments was obtained from the Animal Subjects
Review Board of the University of Florence, in compliance with the
Guide for the Care and Use of Laboratory Animals of the NIH
(USA). All efforts were made to minimize animal suffering and to
reduce the number of animals used. A randomization of animals
between groups and treatments was carried out. The investigators
responsible for data analysis were blind to which animals represented
treatments and controls.
Female X. laevis were sourced from Nasco (Fort Atkinson, WI),
and a maximum of three frogs were kept in purpose-built 15 L
aquarium at 20−26 °C with a 12 h light/dark cycle. Oocytes were
obtained from three frogs (five years old) anaesthetized with 1.7 mg/
mL ethyl 3-aminobenzoate methanesulfonate (pH 7.4 with
NaHCO3), and for recovery, post-surgery animals were placed in
fresh water at a level below the nostrils. Frogs were allowed to recover
for a minimum of four months between surgeries. Terminal anesthesia
with 5 mg/mL ethyl 3-aminobenzoate methanesulfonate (pH 7.4 with
NaHCO3) was performed on frogs at the sixth surgery. All procedures
were approved by the Animal Ethics Committees from University of
Wollongong, University of Sydney, and Universidad de Buenos Aires.
Treatment of PAM-2 and DM489 on Streptozotocin-
Induced Neuropathic Pain. To develop neuropathic pain, mice
(n = 10/condition) were treated with a single intraperitoneal (ip)
injection of 100 mg/kg streptozotocin (STZ) [dissolved in 0.1 M
citrate buffer, pH 4.5 (vehicle)] on day 1 after overnight fasting as
described previously.17,18 The solution of STZ was prepared
immediately before the injection. Control animals received an
equivalent volume of vehicle. Three days later, glycemia was measured
by blood sampling from the caudal vein and analyzed with the Accu-
Check Aviva planar sensor (glucose oxidase method; Roche, Italy).
STZ-treated animals with blood glucose levels <270 mg/dL were
rejected from the study. Animals were then group-housed with full
access to food and water for 2 weeks. To maintain cleanliness and
avoid the development of any infection due to excessive urination,
animal bedding was frequently changed. On day 15, the pain
threshold was evaluated by the cold plate test at 0, 15, 30, 45, and 60
min, revealing significant hypersensitivity of STZ-treated animals.
Mice were then per os (p.o.) administrated with PAM-2 (1 and 3 mg/
kg) or DM489 (3 and 10 mg/kg) [each suspended in 1%
carboxymethylcellulose (i.e., vehicle)], and the anti-nociceptive
activity of these compounds was subsequently evaluated by the cold
plate test.
Treatment of PAM-2 and DM489 on Oxaliplatin-Induced
Neuropathic Pain. To develop neuropathic pain, mice (n = 10/
condition) were administered (ip) with 2.4 mg/kgoxaliplatin
[dissolved in 5% glucose solution (vehicle)] on days 1−3, 6−10,
and 13−14.3,5 Control animals received an equivalent volume of
vehicle. On day 15, the pain threshold was evaluated by the cold plate
test at 0, 15, 30, 45, and 60 min, revealing significant hypersensitivity
of oxaliplatin-treated animals. Mice were then administrated (p.o.)
with PAM-2 (1 and 3 mg/kg) or DM489 (10 and 30 mg/kg) [each
suspended in 1% carboxymethyl cellulose (i.e., vehicle)], and the pain
threshold was subsequently determined by the cold plate test.
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Coadministration of PAM-2 and Oxaliplatin. To determine
whether PAM-2 decreases the development of neuropathic pain
induced by oxaliplatin, mice (n = 10/condition) were coadministered
with 2.4 mg/kg oxaliplatin and an inactive dose of PAM-2 (1 mg/kg;
p.o.) following the same protocol as that for oxaliplatin alone. Pain
threshold values corresponding to 7 and 14 days of cotreatment were
determined 24 h after the last administration by using the cold plate
test. To determine whether an additional administration of PAM-2
increases its efficacy, animals were administered with 1 mg/kg PAM-2
after 30 min of the last cotreatment/cold plate test, and the pain
threshold was subsequently assessed.
Effect of Methyllycaconitine on the Anti-Neuropathic Pain
Activity Mediated by PAM-2 and DM489. To determine whether
the anti-neuropathic pain activity elicited by 3 mg/kg PAM-2 or 30
mg/kg DM489 is mediated by α7 nAChRs, mice (n = 10/condition)
were administered (ip) with 6 mg/kg methyllycaconitine (MLA), an
α7-selective antagonist,24 15 min before the tested drug or vehicle.
Pain threshold measurements were performed at 15, 30, 45, and 60
min after treatment by using the cold plate test.
Cold Plate Test. The animals were placed in a stainless steel box
(12 cm × 20 cm × 10 cm) with a cold plate as the floor. The
temperature of the cold plate was kept constant at 4 ± 1 °C. Pain-
related behavior (licking of the hind paw) was observed, and the time
(s) of the first sign was subsequently recorded (i.e., licking latency).
The cutoff time of the latency of paw lifting or licking was set at 60 s.5
Comparative Activity of PAM-2 and DM489 at Human and
Rat α7 nAChRs Heterologously Expressed in Xenopus laevis
Oocytes. Stage V−VI oocytes (Dumont’s classification; 1200−1300
μm in diameter) were obtained from X. laevis, defolliculated with 1.5
mg/mL collagenase Type II at RT (21−24 °C) for 1−2 h in OR-2
solution containing (in mM) 82.5 NaCl, 2 KCl, 1 MgCl2, and 5
HEPES, at pH 7.4. Oocytes were injected with 10 ng of either human
(h) α7 or rat (r) α7 cRNAs (concentration confirmed spectrophoto-
metrically and by gel electrophoresis) using glass pipettes (3-000-203
GX, Drummond Scientific Co., Broomall, PA). For the synthesis of α7
nAChR subunit cRNAs, plasmid pMXT construct of hα7 and plasmid
pNKS2 construct of rα7 were linearized with BamHI (NEB, Ipswich,
MA) and XbaI (NEB), respectively, for in vitro SP6 mMessage
mMachine-cRNA transcription (AMBION, Foster City, CA). Both
α7 nAChR constructs were sourced from Prof. J. Lindstrom
(University of Pennsylvania, Philadelphia, PA).
Oocytes were incubated at 18 °C in sterile ND96 solution
composed of (in mM) 96 NaCl, 2 KCl, 1 CaCl2, 1 MgCl2, and 5
HEPES, pH 7.4, supplemented with 5% FBS, 0.1 mg/mL gentamicin,
and 100 U/mL penicillin−streptomycin. Electrophysiological record-
ings were carried out 2−7 days post-cRNA microinjection. Two-
electrode voltage clamp recordings of X. laevis oocytes expressing α7
nAChRs were performed at room temperature (RT) using a
GeneClamp 500B amplifier and pClamp9 software interface
(Molecular Devices, San Jose, CA) at a holding potential of −80
mV. Voltage-recording and current-injecting electrodes were pulled
from GC150T-7.5 borosilicate glass (Harvard Apparatus, Holliston,
MA) and filled with 3 M KCl, giving resistances of 0.3−1 MΩ.
Oocytes expressing α7 nAChRs were perfused with ND96 solution
at a rate of 2 mL/min. Initially, oocytes were briefly washed with
ND96 solution followed by three applications of ACh at
concentrations corresponding to the 20% maximal effective
concentration (i.e., EC20) for hα7 (30 μM) and rα7 (160 μM)
nAChRs (Figure 7B), respectively, and 3 min washout between ACh
applications. The ACh EC20 value used for hα7 was calculated from
reported ACh EC50,
32 whereas the rα7 ACh EC20 (160 μM) was
calculated from the concentration−response curve obtained for this
subtype (see Figure 7B).
Peak current amplitudes before and after incubation were measured
using Clampfit 10.7 software (Molecular Devices), and the relative
current amplitude, IACh+compound/IACh (Λ), was used to assess the
compound’s activity at nAChRs. Solutions containing the compound
were prepared in ND96 + 0.1% FBS. Oocytes were incubated with
PAM-2 or DM489 for 5 min with the perfusion system stopped,
followed by coapplication of ACh plus the compound with flowing
bath solution. Incubation with 0.1% FBS was performed to ensure
that the FBS and the pressure of the perfusion system had no effect on
nAChRs.
Voltage Clamp Recordings of Oocytes Expressing rα9α10
nAChRs. For the expression studies, rα9 and rα10 subunits were
subcloned into a modified pGEMHE vector. Capped cRNAs were in
vitro transcribed from linearized plasmid DNA templates using
RiboMAX Large Scale RNA Production System (Promega, Madison,
WI). The maintenance of X. laevis and the preparation and cRNA
injection of stages V and VI oocytes have been described in detail
elsewhere.33 Typically, oocytes were injected with 50 nL of RNase-
free water containing 0.01−1.0 ng of cRNA (at a 1:1 molar ratio when
pairwise combined) and maintained in Barth’s solution at 18 °C.
Electrophysiological recordings were performed 2−6 days after cRNA
injection under two-electrode voltage clamp with an Oocyte Clamp
OC-725B or C amplifier (Warner Instruments Corp., Hamden, CT).
Recordings were filtered at a cutoff frequency of 10 Hz using a 900BT
Tunable Active Filter (Frequency Devices Inc., Ottawa, IL). Data
acquisition was performed using a Patch Panel PP-50 LAB/1
interphase (Warner Instruments Corp., Hamden, CT) at a rate of
10 points/s. Both voltage and current electrodes were filled with 3 M
KCl and had resistances of ∼1 MΩ. Data were analyzed using
Clampfit from the pClamp 6.1 software. During electrophysiological
recordings, oocytes were continuously superfused (∼15 mL/min)
with normal frog saline containing (in mM) 115 NaCl, 2.5 KCl, 1.8
CaCl2, and 10 HEPES, pH 7.2. ACh and PAM-2 or DM489 were
added to the perfusion solution. Unless otherwise indicated, the
membrane potential was held at −70 mV. To minimize endogenous
Ca2+-dependent chloride currents, oocytes were incubated with the
Ca2+ chelator BAPTA-AM (100 μM) for 3 h before electro-
physiological recordings. PAM-2 and DM489 concentration-inhib-
ition curves were performed on ACh-activated α9α10 nAChRs, using
a concentration of ACh (i.e., 10 μM) corresponding to its EC50 value.
Oocytes were preincubated for 2 min with the compound under study
before adding ACh + compound.
Current−voltage (I−V) relationships in the absence and presence
of 30 μM DM489 were obtained by applying 2 s voltage ramps from
−120 to +50 mV, 10 s after the peak response to 10 μM ACh from a
holding potential (Vhold) of −70 mV. Leakage correction was
performed by subtraction of the I−V curve obtained by the same
voltage ramp protocol before the application of ACh. Data were
analyzed using Clampfit from the pClamp 6.1 software.
Whole-Cell Patch Clamp Recording of HEK293T Cells
Expressing CaV2.2 Channels Alone or Coexpressing GABABRs.
HEK293T cells (ATCC, Manassas, VA) were cultured in DMEM
supplemented with 10% FBS, 1% penicillin and streptomycin, and 1×
GlutaMAX at 37 °C in 5% CO2. Cells were plated on 12 mm glass
coverslips and transiently transfected using the calcium phosphate
method. The tricistronic plasmid cDNA3.1 construct containing
human GABABR1 and GABABR2 subunits, and the green fluorescent
protein (GFP), was cotransfected with plasmid cDNA3.1 constructs
encoding hCaV2.2 α1B, α2δ1, and β3 subunits (all constructs were in-
house generated) at 2 μg each. The plasmid construct of GFP (0.5
μg) was only cotransfected with pCDNA3.1 constructs of CaV2.2
α1B, α2δ1, and β3 subunits for the identification of transfected cells.
Whole-cell patch clamp recordings were performed within 24−48 h
post-transfection at RT (21−23 °C). Cells were constantly superfused
using a gravity flow perfusion system (AutoMate Scientific, Berkeley,
CA) with extracellular solution containing (in mM) 110 NaCl, 10
BaCl2, 1 MgCl2, 5 CsCl, 30 TEA-Cl, 10 glucose, and 10 HEPES (pH
7.35 with TEA−OH; ∼310 mOsmol/kg). Fire-polished borosilicate
patch pipettes (2−3 MΩ) were filled with intracellular solution
containing (in mM) 125 K-gluconate, 5 NaCl, 2 MgCl2, 5 EGTA, and
10 HEPES (pH 7.2 with KOH; ∼290 mOsmol/kg). Inward Ba2+
currents were elicited by a test depolarization to −10 mV (50 ms
duration) from a holding potential of −80 mV applied at 0.1 Hz.
Solutions containing PAM-2 or DM489 were prepared in the external
solution.
Statistical Analysis of Data. The concentration−response
relationship for PAM-2 and DM489 was analyzed using the Prism 7
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software (GraphPad, La Jolla, CA) according to one- and two-
component (see eq 1) Hill equation:
= + Δ × [ ] [ ] +
+ − Δ × [ ] [ ] +
I E
I E
100 comp /( comp EC )








where Icomp is the current in the presence of the compound (expressed
as% of control current), ΔEmax is the maximal potentiating effect
(compound efficacy; considering control 100%), Isat is the current at
saturating compound concentration (expressed as% control), [comp]
is the compound concentration, nH is the Hill coefficient, EC50 is the
compound concentration to produce 50% potentiation, and IC50 is
the compound concentration to produce 50% inhibition.
The inhibition of rα9α10 nAChRs determined at different voltage
values was compared by paired Student’s t test. Values of P < 0.05
were considered statistically significant. One-way ANOVA analyses
and the subsequent Bonferroni post hoc comparison of the behavioral
data were assessed by using the Origin 9 software (OriginLab Corp.,
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inhibition; nH, Hill coefficient; FBS, fetal bovine serum
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